The hospice M&A landscape: who's consolidating, and why

The largest hospice operator in the country runs about 1.5% of the market. That is not a sign the roll-up is over. It is the reason it keeps running. Hospice is the most fragmented sector in post-acute and one of the most actively traded, and those two facts are the whole thesis: a long tail of independent providers, a high-margin per-diem model, and a deep bench of buyers competing to consolidate it.

• Largest operator — 1.5% · Amedisys, 63 facilities in-file
• Deals since 2019 — 337 · Peak of 71 in 2020
• Median multiple — 10.0x · EBITDA; about 12x since 2021
• Distinct operators — 387 · Two-thirds run a single location

How fragmented hospice really is

Across roughly 4,000 Medicare-certified hospices in the cost-report data, 387 distinct operators are identifiable, and the largest, Amedisys, accounts for only about 1.5% of facilities. The ten largest operators together hold 8.1%, the twenty-five largest 12.4%, and nearly two-thirds of named operators run a single location. By in-file footprint, the largest are Amedisys (63 facilities), CH Services (60), Enhabit (45), and VITAS Healthcare (30). Read those as an in-dataset ranking, not a national tally.

That is a more fragmented market than skilled nursing, where the top ten hold 12.7%. In hospice there is no dominant incumbent, no operator with the scale to set the market, and a very long tail of small providers. For a consolidator, that is the ideal starting board: plenty of targets, and no gatekeeper large enough to block a roll-up.

Who is consolidating it

The buyers are active and repeat. In Scope Research's deal register, more than 330 hospice transactions have closed since 2019. Volume peaked at 71 deals in 2020, cooled through 2022 and 2023 as financing tightened, and has settled into the 30s and 40s a year since. The pace reflects a market that ran hot, repriced, and kept moving rather than stopping.

The consolidators are a recognizable set of platforms. The most acquisitive buyers since 2019 include Traditions Health, Bristol Hospice, The Pennant Group, St. Croix Hospice, Care Hospice, and Three Oaks Hospice, most of them private-equity-backed platforms built specifically to roll up regional hospices. Pennant and the former LHC Group, now inside Optum, are the public strategics in the mix. These are not one-time buyers. Several have closed a dozen or more deals apiece, assembling national footprints one regional provider at a time, which is exactly how a fragmented sector consolidates when no single starting operator is large.

What buyers are paying

Priced hospice deals clear at a premium to the rest of post-acute. Across the hospice transactions with a reliable multiple in Scope Research's valuation set, the median price is about 10 times EBITDA and 1.4 times revenue, on a sample of 56 and 72 deals respectively. Recent deals have run firmer: since 2021 the median sits closer to 12 times EBITDA. The spread is wide, because deal size drives it. Small regional tuck-ins change hands below 1 times revenue, while scaled, clean-compliance platforms command the top of the range.

• Multiple — Median · Middle half · n
• Price to EBITDA — 10.0x · 8.0x to 13.2x · 56
• Price to revenue — 1.4x · 1.0x to 2.1x · 72

Deals with a disclosed, reliable multiple only. Small samples: read as directional.

The marquee deals set the ceiling. Those are strategic and sponsor buyers paying up for scale and a clean book, and they sit well above the 8-to-10-times range where a typical regional hospice trades.

• Named deal — EBITDA · Revenue
• Amedisys / UnitedHealth (Optum) — 15.2x · 1.6x
• Agape Care / Linden Capital — ~18x · n/a
• Covenant / Chemed (VITAS) — ~18x · n/a
• Three Oaks / Martis Capital — 13.5x · n/a
• Enhabit / Kinderhook — 10.1x · n/a

UnitedHealth's Optum bought Amedisys at roughly 1.6 times revenue and 15 times EBITDA. Linden Capital's acquisition of Agape Care and Chemed's VITAS buying Covenant both priced near 18 times EBITDA, and Martis Capital's purchase of Three Oaks landed around 13 times.

Strategics vs. private equity

Both kinds of buyer are in the market, and they play different roles. Among priced hospice deals, strategic buyers, public and private operators expanding their own footprints, account for the majority, while financial sponsors make up a smaller but higher-profile share. The pattern underneath is that strategics tend to do the largest, headline deals, while private-equity-backed platforms drive the steady stream of regional bolt-ons that actually consolidates the tail.

Sizing private equity precisely is not possible from public data. The cost-report ownership flag captures identified sponsors only and undercounts real PE presence, and many hospice acquisitions close under holding-company or acquisition-entity names rather than a recognizable operator. The honest way to read it is by named platform and sponsor, not a penetration rate: Bristol Hospice under Webster Equity, St. Croix under H.I.G. Capital, Agape under Linden Capital, and Three Oaks under Martis are among the identifiable PE-backed consolidators. Treat any clean "share of hospices owned by PE" figure as a floor, not a count.

What makes hospice an attractive target

The appeal comes down to the economics the pillar lays out. Hospice runs the highest median margin in post-acute, about 10% EBITDA, and because the model is asset-light, most of that reaches the operating line rather than a rent line. Revenue is a predictable Medicare per-diem, census scales without a fixed bed ceiling, and the sector is fragmented enough to give a platform years of runway. Put those together and you have durable cash flow, a clear growth lever in census, and a deep supply of targets, which is what a financial sponsor underwrites and what a strategic pays up for.

The constraint is quality and compliance, not availability. Compliant assets are scarcer than the raw target count suggests.

A federal 36-month rule blocks the quick resale of newly certified hospices, and program-integrity scrutiny concentrated in a few states has made a clean survey and admission history a gating condition. Length-of-stay mix, live-discharge rates, and aggregate-cap exposure are the diligence items that decide whether a high-margin book is actually buyable. For how those economics work, see hospice economics; for the volume metric behind the model, see what average daily census is.

Sources and method

• Operator data — CMS HCRIS provider cost reports, FY2024-2025; 4,068 hospice facility rows excluding consolidated filings; 387 distinct operators
• Deal volume — Scope Research Healthcare M&A Volume Database; 337 hospice transactions, 2019-2026, with 2026 partial
• Multiples — Scope Research Healthcare M&A Valuation Database; deals with a disclosed, reliable price-to-revenue or price-to-EBITDA figure
• Sample sizes — 56 deals on EBITDA and 72 on revenue; small samples, read as directional and do not over-read a single year or deal
• Private equity — The cost-report ownership flag captures identified sponsors only and undercounts; no penetration rate is published
• Known limits — Cost-report figures are self-reported and unaudited; in-file operator counts are dataset footprints, not national totals

Full methodology and limitations

Disclaimer

This article is a market-data benchmarking resource derived from publicly available Medicare cost reports and third-party M&A data. It does not provide, and must not be relied upon as, a fair market value determination, valuation opinion, appraisal, or legal, tax, or compliance advice. Cost-report figures are self-reported, unaudited, and subject to revision. The opinion of value for any specific arrangement remains the professional judgment of a qualified appraiser.